ArticleScientific reports2025
Effects of ulinastatin on therapeutic outcomes and inflammatory markers in pediatric septic shock patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of meropenem plus ulinastatin on inflammatory response and complications in patients with severe septic shock.Frontiers in medicine · 2026Article
- Article
- Incidence and risk factors for postoperative pulmonary complications in children following surgery for retroperitoneal neuroblastoma.Frontiers in pediatrics · 2026Article
- Deriving consensus sepsis clusters via goal-directed subgroup identification in multi-omics study.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the effects of ulinastatin on therapeutic outcomes and inflammatory markers in children with septic shock. This study selected 117 children with septic shock admitted to our hospital from April 2023 to April 2024. Among them, 7 children had comorbidities, 3 dropped out during the research process, 5 did not continue to participate in the study due to other reasons, and 4 explicitly refused to participate. After screening and excluding the above - mentioned cases, A total of 98 children were allotted to experimental group (ulinastatin combined with routine antishock therapy, n = 49) and control group (routine antishock therapy, n = 49) using stratified random method. The therapeutic effects and levels of inflammatory markers were assessed before and after treatment using a double antibody sandwich ELISA. The outcome was significantly better in the experimental group compared to controls (P < 0.05). Prior to treatment, there were no significant differences in the levels of CD64, procalcitonin (PCT), C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and serum α-hydroxybutyrate dehydrogenase between the two groups (all P > 0.05). After 7 days of treatment, the experimental group exhibited significantly lower levels of CD64, PCT, C-reactive protein, NLR, and serum α-hydroxybutyrate dehydrogenase compared to the control group (all P < 0.001). Ulinastatin enhances the therapeutic efficacy in children with septic shock by reducing levels of associated inflammatory markers and promoting recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.